Research & Literature

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Barbui T, Thiele J, Vannucchi AM, Tefferi A

Blood cancer journal 2015; (5()):e337 doi:10.1038/bcj.2015.64.

Coexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case report.

Jeong G, Kim J, Han S, et al.

Oncology letters 2016; (11(2)):1469-1473 doi:10.3892/ol.2015.4040.

Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.

Hyrenius-Wittsten A, Sturesson H, Bidgoli M, et al.

Genes, chromosomes & cancer 2016; (55(11)):847-54 doi:10.1002/gcc.22384.

The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Gianelli U, Cattaneo D, Bossi A, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(2)):169-179 doi:10.1038/modpathol.2016.182.

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R

Blood 2017; (129(6)):667-679 doi:10.1182/blood-2016-10-695940.

Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.

Gowin K, Jain T, Kosiorek H, et al.

Leukemia research 2017; (54()):73-77 doi:10.1016/j.leukres.2017.01.006.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, et al.

Annals of hematology 2017; (96(10)):1653-1665 doi:10.1007/s00277-017-3082-y.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, et al.

Leukemia 2018; (32(5)):1200-1210 doi:10.1038/s41375-018-0019-y.

Polycythemia Vera.

Spivak JL

Current treatment options in oncology 2018; (19(2)):12 doi:10.1007/s11864-018-0529-x.

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.

De Stefano V, Finazzi G, Barbui T

Blood cancer journal 2018; (8(7)):65 doi:10.1038/s41408-018-0101-8.

Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.

Trifan G, Shafi N, Testai FD

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018; (27(10)):2572-2578 doi:10.1016/j.jstrokecerebrovasdis.2018.05.052.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.

Mesa R, Boccia RV, Grunwald MR, et al.

Clinical lymphoma, myeloma & leukemia 2018; (18(9)):590-596 doi:10.1016/j.clml.2018.05.020.

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.

Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al.

BMC cancer 2019; (19(1)):184 doi:10.1186/s12885-019-5387-9.

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.

McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, et al.

British journal of haematology 2020; (190(3)):437-441 doi:10.1111/bjh.16537.

Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?

Sangiorgio VFI, Orazi A, Arber DA

Best practice & research. Clinical haematology 2020; (33(2)):101139 doi:10.1016/j.beha.2019.101139.

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

Talpaz M, Kiladjian JJ

Leukemia 2021; (35(1)):1-17 doi:10.1038/s41375-020-0954-2.

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.

Padrnos L, Scherber R, Geyer H, et al.

Cancer medicine 2020; (9(22)):8301-8309 doi:10.1002/cam4.3380.

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.

Tefferi A

American journal of hematology 2021; (96(1)):145-162 doi:10.1002/ajh.26050.

Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark.

Brochmann N, Flachs EM, Christensen AI, et al.

Cancers 2020; (12(12)) doi:10.3390/cancers12123565.

Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.

Guaraná M, Soares A, Daumas A, et al.

Hematology, transfusion and cell therapy 2022; (44(3)):321-327 doi:10.1016/j.htct.2020.10.966.

Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.

Deschamps P, Moonim M, Radia D, et al.

British journal of haematology 2021; (193(4)):792-797 doi:10.1111/bjh.17375.

Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.

Maddali M, Kulkarni UP, Ravindra N, et al.

Hematology/oncology and stem cell therapy 2022; (15(2)):13-20 doi:10.1016/j.hemonc.2021.03.002.

Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study.

Rossau HK, Kjerholt M, Brochmann N, et al.

Journal of clinical nursing 2022; (31(7-8)):909-921 doi:10.1111/jocn.15944.

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.

Langlais BT, Mazza GL, Kosiorek HE, et al.

Journal of hematology 2021; (10(5)):207-211 doi:10.14740/jh914.

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.

Pizzi M, Croci GA, Ruggeri M, et al.

Cancers 2021; (13(22)) doi:10.3390/cancers13225666.

How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.

McLornan DP, Hargreaves R, Hernández-Boluda JC, Harrison CN

British journal of haematology 2022; (197(4)):407-416 doi:10.1111/bjh.18087.

Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.

Hargreaves R, Harrison CN, McLornan DP

Current research in translational medicine 2022; (70(3)):103338 doi:10.1016/j.retram.2022.103338.

How I Diagnose Primary Myelofibrosis.

Prakash S, Orazi A

American journal of clinical pathology 2022; (157(4)):518-530 doi:10.1093/ajcp/aqac016.

Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.

Bhuria V, Baldauf CK, Schraven B, Fischer T

International journal of molecular sciences 2022; (23(6)) doi:10.3390/ijms23063206.

Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.

Htun HL, Lian W, Wong J, et al.

Cancer epidemiology 2022; (79()):102175 doi:10.1016/j.canep.2022.102175.

Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.

Maddali M, Venkatraman A, Kulkarni UP, et al.

Annals of hematology 2022; (101(9)):1987-2000 doi:10.1007/s00277-022-04920-w.

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.

Thiele J, Kvasnicka HM, Orazi A, et al.

American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.

Addressing symptom burden in myeloproliferative neoplasms.

Tremblay D, Mesa R

Best practice & research. Clinical haematology 2022; (35(2)):101372 doi:10.1016/j.beha.2022.101372.

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.

Patnaik MM, Tefferi A

American journal of hematology 2023; (98(4)):681-689 doi:10.1002/ajh.26828.

Trends in overall mortality among US veterans with primary myelofibrosis.

Tashi T, Yu J, Pandya S, et al.

BMC cancer 2023; (23(1)):48 doi:10.1186/s12885-022-10495-6.

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2023; (98(5)):801-821 doi:10.1002/ajh.26857.

Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation.

Suknuntha K, Geyer JT, Patel KP, et al.

Leukemia research 2023; (127()):107033 doi:10.1016/j.leukres.2023.107033.

Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.

Le Gall-Ianotto C, Ficheux AS, Lippert E, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(6)):1175-1183 doi:10.1111/jdv.18990.

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].

Yan X, Qin TJ, Li B, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2023; (44(4)):276-283 doi:10.3760/cma.j.issn.0253-2727.2023.04.003.

Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.

Tefferi A, Barbui T

American journal of hematology 2023; (98(9)):1465-1487 doi:10.1002/ajh.27002.

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

Hudgens S, Verstovsek S, Floden L, et al.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2024; (27(5)):607-613 doi:10.1016/j.jval.2024.01.014.

Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment.

Custo S, Tabone E, Aquilina A, et al.

Hamostaseologie 2024; (44(4)):242-254 doi:10.1055/a-2232-5480.

Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study.

Crane GM, Geyer JT, Thakral B, et al.

American journal of clinical pathology 2024; (162(3)):233-242 doi:10.1093/ajcp/aqae033.

The personal impact of living with a myeloproliferative neoplasm.

Eppingbroek AAM, Lechner L, Bakker EC, et al.

Psycho-oncology 2024; (33(4)):e6338 doi:10.1002/pon.6338.

Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.

Szuber N, Orazi A, Tefferi A

American journal of hematology 2024; (99(7)):1360-1387 doi:10.1002/ajh.27321.

Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report.

Chen Y, Kong BB, Yin H, et al.

World journal of clinical cases 2024; (12(15)):2621-2626 doi:10.12998/wjcc.v12.i15.2621.

Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review.

Song J, Huang C, Jia L, et al.

BMC neurology 2024; (24(1)):386 doi:10.1186/s12883-024-03913-8.

Diagnosis and Treatment of Polycythemia Vera: A Review.

Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R

JAMA 2025; (333(2)):153-160 doi:10.1001/jama.2024.20377.

Distress and Care Utilization in Patients with Myeloproliferative Neoplasms.

Patel R, Patel RV, Boselli D, et al.

Acta haematologica 2025; (148(6)):690-698 doi:10.1159/000544162.

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

Polverelli N, Hernández-Boluda JC, Onida F, et al.

Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms.

Prakash S, Orazi A

Advances in anatomic pathology 2025; (32(4)):284-298 doi:10.1097/PAP.0000000000000493.

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms.

Guo X, Jia W, Yang X, et al.

Translational oncology 2025; (58()):102441 doi:10.1016/j.tranon.2025.102441.

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.

Iurlo A, Cattaneo D, Gianelli U, Passamonti F

HemaSphere 2025; (9(12)):e70270 doi:10.1002/hem3.70270.

Concurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations.

Li Q, Tan L, Wang X, Fan Q

Case reports in hematology 2025; (2025()):9728317 doi:10.1155/crh/9728317.

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.

Machherndl-Spandl S, Kiehberger M, Sygulla V, et al.

Cancers 2025; (17(24)) doi:10.3390/cancers17243940.

Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.

Oganesyan A, Madero-Marroquin R, Patel AA

Current opinion in hematology 2026; (33(2)):45-50 doi:10.1097/MOH.0000000000000907.

Management of Splanchnic Venous Thrombosis: An Update.

Rühl H, Reda S

Hamostaseologie 2026; (46(1)):71-77 doi:10.1055/a-2749-6835.

Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective.

Cohen O, Ellis MH

Seminars in thrombosis and hemostasis 2026; doi:10.1055/a-2836-0670.

Long-term outcomes of ropeginterferon alfa-2b-njft in polycythemia vera: a review of safety, efficacy, and potential disease modification.

Abu-Zeinah G, Reeves B

Leukemia & lymphoma 2026; (67(7)):1492-1501 doi:10.1080/10428194.2026.2666851.

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Arora S, Senapati J, Deshmukh I, et al.

Journal of hematology & oncology 2026; (19(1)).